Tirzepatide may modify obesity-related OSA beyond weight loss via inflammation and ventilatory control.

Obesity is a primary driver of obstructive sleep apnea (OSA), a chronic condition traditionally viewed as a mechanical disorder characterized by recurrent upper airway collapse during sleep. However, growing evidence supports a broader pathophysiological model that extends beyond anatomical obstruction, implicating metabolic dysfunction, systemic inflammation, and ventilatory instability as key contributors. Current standard-of-care, often continuous positive airway pressure (CPAP), effectively manages symptoms but does not address the underlying disease progression or its cardiometabolic comorbidities. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated substantial weight loss and comprehensive cardiometabolic benefits, raising the possibility of a paradigm shift in OSA management by targeting these fundamental disease mechanisms.

To critically evaluate the potential of tirzepatide as a disease-modifying therapy in obesity-related OSA beyond its effects on weight reduction, a comprehensive narrative review was conducted. Researchers systematically searched major bibliographic databases including PubMed, Scopus, and Web of Science for relevant literature published up to January 2026. The synthesis focused on evidence derived from randomized controlled trials, meta-analyses, and mechanistic studies concerning incretin-based therapies in the context of obesity and OSA, with particular emphasis on reported clinical outcomes and the elucidation of underlying biological pathways.

The synthesized evidence indicates that Tirzepatide is consistently associated with significant reductions in the apnea-hypopnea index (AHI), a primary measure of OSA severity, alongside substantial and well-documented weight loss. > Crucially, emerging data from various studies suggest that the observed improvements in OSA severity may not be entirely explained by weight reduction alone, pointing towards potential weight-independent therapeutic effects. These hypothesized mechanisms include the modulation of systemic inflammation, leading to a reduction in pro-inflammatory cytokines, significant improvements in insulin sensitivity and glucose homeostasis, and beneficial alterations in adipokine profiles (e.g., leptin and adiponectin). Furthermore, tirzepatide appears to exert effects on autonomic regulation and ventilatory control, potentially enhancing upper airway stability and improving chemosensitivity. These pleiotropic actions collectively influence key components of OSA pathophysiology, offering a more comprehensive approach to treatment. Despite these compelling findings, the review concludes that current evidence remains insufficient to definitively distinguish the precise contribution of weight-dependent versus weight-independent effects.